Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Iacoboni, Gloria, Villacampa, Guillermo, Martinez‐Cibrian, Nuria, Bailén, Rebeca, Lopez Corral, Lucia, Sanchez, Jose M., Guerreiro, Manuel, Caballero, Ana Carolina, Mussetti, Alberto, Sancho, Juan‐Manuel, Hernani, Rafael, Abrisqueta, Pau, Solano, Carlos, Sureda, Anna, Briones, Javier, Martin Garcia‐Sancho, Alejandro, Kwon, Mi, Reguera‐Ortega, Juan Luis, Barba, Pere
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2021
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124109/
https://ncbi.nlm.nih.gov/pubmed/33932100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3881
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia